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Abstract
Background
In the United States whites are more likely to misuse opioid pain relievers (OPRs) than
blacks, and blacks are less likely to be prescribed OPRs than whites. Our objective is to
determine whether racial discrimination in medical settings is protective for blacks against
OPR misuse, thus mediating the black-white disparities in OPR misuse.
Methods
We used data from 3528 black and white adults in the Coronary Artery Risk Development in
Young Adults (CARDIA) study, an ongoing multi-site cohort. We employ causal mediation
methods, with race (black vs white) as the exposure, lifetime discrimination in medical set-
tings prior to year 2000 as the mediator, and OPR misuse after 2000 as the outcome.
Results
We found black participants were more likely to report discrimination in a medical setting
(20.3% vs 0.9%) and less likely to report OPR misuse (5.8% vs 8.0%, OR = 0.71, 95% CI =
0.55, 0.93, adjusted for covariates). Our mediation models suggest that when everyone is
not discriminated against, the disparity is wider with black persons having even lower odds
of reporting OPR misuse (OR = 0.63, 95% CI = 0.45, 0.89) compared to their white
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counterparts, suggesting racial discrimination in medical settings is a risk factor for OPR
misuse rather than protective.
Conclusions
These results suggest that racial discrimination in a medical setting is a risk factor for OPR
misuse rather than being protective, and thus could not explain the seen black-white dispar-
ity in OPR misuse.
Introduction
Drug overdose death rates within the United States nearly tripled between 1999 and 2015[1].
Vital records data, opioid sales data, and other sources suggests that a large portion of this
increase in deaths is attributable to legally produced, pharmaceutical Opioid Pain Relievers
(OPRs) such as oxycodone, hydromorphone and oxymorphone[2, 3]. The National Institute
on Drug Abuse (NIDA) defines misuse of prescription drugs as “taking a medication in a man-
ner or dose other than prescribed; taking someone else’s prescription, even if for a legitimate
medical complaint such as pain; or taking a medication to feel euphoria (i.e., to get high)”[4].
During the prescription opioid epidemic, death rates attributed to OPR overdose among
whites have been more than twice that of the rates seen among blacks[3], and whites have had
significantly higher rates of hospitalization due to OPRs than blacks[5]. The black and white
disparity in drug related overdose deaths in the 2000s was drastically different than it was in
the 1990s[1]. According to CDC mortality files, in 1999 blacks were more likely to overdose
from drug induced causes than whites, however around 2002 the rate for whites overtook the
rate for blacks[1, 6], and by 2015 mortality rates for whites were approximately 1.5 times
higher than blacks[1]. From the 1990s to early 2010s OPR misuse was attributable mostly or in
part to patterns of OPR overprescribing in the United States[2]. The sales of OPRs within the
United States increased by almost 500% between 1999 and 2011 and the same time the rates of
OPR related deaths were tripling[2]. Given this knowledge, it would follow that any racial/eth-
nic disparities in OPR misuse could be related to disparities in OPR prescribing, based on the
premise that less prescribing for minorities might result in fewer opportunities for misuse. A
recent review paper found that across 70 studies of prescribing patterns, racial and ethnic
minorities received less treatment for acute and chronic pain than their white counterparts[7].
A study of disparities in opioid prescribing in pain-related emergency room visits also showed
blacks to have a lower odds of receiving OPRs than whites[8]. These disparities pose several
interesting questions related to discrimination in medical care and drug misuse in the United
States. Perceived interpersonal discrimination (henceforth called discrimination) due to race
within the medical care setting has been associated with negative healthcare service outcomes
and underutilization of preventive services[9, 10]. Using an experimental design and actors
playing cardiac patients, one study found that given identical clinical presentations for white
and black patients, physicians were more likely to recommend white patients for cardiac cathe-
terization than black patients[11]. In another study, Krieger et al. hypothesized that the lack of
prescription of hormone therapy to black women, due to discrimination, was likely the reason
why black women had lower rates of breast cancer in the 1990s before the results of the Wom-
en’s Health Initiative Study showed an association between these hormones and breast cancer
[12]. With these examples in mind, we propose to investigate a research question in which
Racial discrimination in medical care settings and opioid pain reliever misuse
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discrimination in a healthcare setting may actually be protective against negative consequence
of access to healthcare.
The objective of this study is to examine the relationship between race and OPR misuse (i.e.
the black-white disparity), and whether discrimination in a medical setting acts as a mediator
in this relationship, employing causal mediation framework. Following the evidence from the
studies noted above[11, 12], we hypothesized that racial discrimination in a medical setting
would result in under prescribing of OPR to blacks, which would then result in lower OPR
misuse among blacks and thus explain the black-white disparity.
Methods
Study population
CARDIA is an ongoing multisite prospective cohort study of the determinants of clinical and
subclinical cardiovascular disease. In 1985 and 1986 a total of 5,114 black and white adults
were recruited into this study from four field centers which include: The University of Ala-
bama at Birmingham, The University of Minnesota, Northwestern University, and Kaiser Per-
manente in Oakland California. Participants were followed from 1985–86 to the present with
follow up visits in 1987–88, 1990–91, 1992–93, 1995–96, 2000–01, 2005–06, 2010–11, and
2015–16. Details of the study design are described elsewhere[13]. The CARDIA study was IRB
approved at each field center, and written informed consent was obtained from each partici-
pant at each examination. This secondary analysis of de-identified data was approved by the
CARDIA Publications and Presentations Subcommittee. CARDIA data can be accessed after a
manuscript proposal and request for data acquisition are approved by the appropriate Presen-
tations and Publications (P&P) committee.
Perceived discrimination in a medical setting prior to year 2000
Discrimination is measured using the Experiences of Discrimination (EOD) instrument,
which has been previously validated[14]. The discrimination questions were asked in years
1992, 2000, 2005, 2010 and 2015. Study participants were asked “have you ever experienced
discrimination, been prevented from doing something, or been hassled, or made to feel infe-
rior in any if the following situations because of your race?”. They were then presented with sit-
uations/domains, which included, “at school,” “getting a job,” “getting housing,” “at work,” “at
home,” “getting medical care,” or “on the street in a public setting”. In this study, we used
racial discrimination in “getting care in a medical setting” (and not in any other setting). We
used discrimination from exam years 1992 and 2000 for our exposure of interest, thus reflect-
ing any lifetime reporting of discrimination up to year 2000. As such, we did not exclude those
who have changed their report of discrimination across the years. We chose to examine dis-
crimination up to year 2000 to examine the influence of prior discrimination on the largest
increases in the black-white disparity in OPR misuse, which happened after the year 2000.
These two exam years were combined to increase the sample size of persons who experienced
discrimination in a medical setting, while we used other approaches/definitions in sensitivity
analyses (described later).
Nonmedical Opioid Pain Reliever (OPR) misuse from 2005 to 2015
CARDIA participants were asked about lifetime illicit drug misuse in all examination years.
For this analysis, we combined lifetime OPR misuse in exam years 2005, 2010 and 2015 as our
outcome, excluding people who reported OPR or opiate misuse in years 2000 and prior. This
allowed us to capture new misusers and that OPR misuse took place after our exposure period
Racial discrimination in medical care settings and opioid pain reliever misuse
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(up to 2000) (defined above). Participants were asked questions related to misuse of illicit opi-
oids such as “Heroin,” and misuse of OPR medications such as “Dilaudid,” “Morphine,”
“Demerol,” “Oxycodone,” “Hydromorphone,” or “other prescription opioids” for non-medical
reasons. In all exam years, participants who reported non-medical use of prescription OPR
medications were included as OPR misusers, and participants who misused only heroin or
other non-prescription illicit opioids were excluded from the OPR misuse group.
Other covariates
Participants reported their race (white vs. black), sex, age, years of educational attainment,
total household income (collected in 8 brackets and treated continuously using the midpoint
dollar amount of bracket), and health insurance status (insured vs. not). Parental SES was
operationalized as the highest level of education in years achieved by any parent or guardian.
Depressive symptoms were measured using the Center for Epidemiological Studies depression
scale (CES-D) instrument, which includes 20 items and ranges from 0–60[15]. All covariates
were measured in year 1992 (study baseline, and when discrimination was first measured),
except for depressive symptoms which was measured in year 1990.
Statistical analysis
Of the 4617 participants who were present at any exam between 1992 and 2015, we excluded
264 participants without a measure of lifetime discrimination in 1992/2000. Since the OPR
question is also a lifetime measure, we further excluded 318 participants who by exam year
2000 had misused OPR at least once in their lifetime, and further excluded 507 participants
with missing OPR measures in 2005, 2010 and 2015. This left a final analytical sample of 3528
persons. As such, for this analysis, we established temporality between exposure and outcome
by defining the exposure period as lifetime medical discrimination prior to year 2000, and the
outcome period as any OPR misuse in years 2005 through 2015.
We first compared black and white participants across our covariate characteristics using
chi-squared tests and t-tests. Next, we used a causal mediation framework to assess whether
there is a racial disparity in OPR misuse, and if so, whether this disparity could be explained by
discrimination. The directed acyclic graph (DAG) for this research question is presented in
Fig 1. Race as the exposure/ treatment (white = 0 (reference), black = 1), discrimination in a
medical care setting as the mediator (M = 1 discrimination, M = 0 no discrimination), and
OPR misuse as the outcome (Y = 1 OPR misuse, Y = 0 no OPR misuse).
We performed causal mediation analysis as described by Valeri and VanderWheele[16], a
method that uses counterfactual contrasts to compute a total effect (TE) and a controlled direct
effect (CDE) for the relationship of interest. The total effect (TE) is the effect of race on OPR
misuse, adjusted for measured confounders; and the controlled direct effect (CDE) is the effect
of race on OPR misuse examining groups of participants who experience the same level of dis-
crimination (either M = 0 or M = 1), adjusted for measured confounders. We focus on the
CDE, comparing the influence of race among participants experiencing no discrimination (M
set to 0). We consider the following variables as confounders of the discrimination–OPR path:
parental SES, sex, age, and study site. Variables such as education, income, depressive symp-
toms, and insurance status are confounders of the discrimination–OPR path but are mediators
of the race–OPR path (see Fig 1).
Since our outcome (OPR misuse) was rare (<10%), we used logistic regression[17] in con-
structing the following four models. In model 1, we calculate the total effect by regressing OPR
misuse on race while adjusting for confounders (parental SES, age, sex, study site). Next, we
calculate the controlled direct effect by comparing three models (models 2 to 4) all of which
Racial discrimination in medical care settings and opioid pain reliever misuse
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are regressing OPR misuse on race while adjusting for discrimination. In controlled direct
effect model 2, we adjust for confounders only. In controlled direct effect model 3, we addi-
tionally adjust for the confounders/mediators. In controlled direct effect model 4, which is a
marginal structural model, we used stabilized inverse probability weights (IPW) to account for
the confounders/mediators (see supplemental material for the SAS code to create the stabilized
treatment weights). The approach for these models is in line with previous mediation analysis
literature[18]. We interpret the coefficient for race as describing the racial inequality in OPR
misuse, and the controlled direct effect as the magnitude of the racial inequality we would
expect if discrimination were absent for both blacks and whites.
We conducted three sensitivity analyses. First, we performed an analysis excluding partici-
pants who reported lifetime discrimination in 1992 but not in 2000, as this pattern while it
could be true, it could also be reflecting measurement error in response to the question. Sec-
ond, we conducted an analysis examining “recent” discrimination rather than lifetime discrim-
ination, by including only persons who reported discrimination in a medical setting in 2000
and not in 1992 or prior. Third, since the opioid epidemic has been characterized by increases
in prescribing of OPRs for various conditions related to both chronic and acute pain[2], we
conducted an analysis adjusting for self-reported pain in year 2000 as a proxy variable for pain
related conditions that may influence OPR misuse. Participants were asked the following ques-
tion: “During the past 4 weeks, how much did pain interfere with your normal work (including
work outside the home and housework)?”; and responses were coded as “no pain, a little bit of
pain to moderate pain, or quite a bit of pain to extreme pain”. All analyses were conducted
using SAS version 9.4 and SAS University Edition Software[19].
Results
As shown in Table 1, black participants were much more likely to report experiencing discrim-
ination in a medical setting (20.3% vs 0.9%) and less likely to report OPR misuse (5.8% vs
Fig 1. Directed acyclic graph for proposed relationship between race, discrimination in a medical care setting, and
OPR misuse.
https://doi.org/10.1371/journal.pone.0226490.g001
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8.0%). Black participants were more likely to be female, have lower incomes, lower educational
attainment, and lower parental SES, and were more likely to have elevated depressive symp-
toms (CES-D�16).
Table 2 displays the results of the causal mediation analysis, in which the influence of dis-
crimination can be understood by comparing the coefficients of the total effect and controlled
direct effects. The total effect suggests that adjusting for all measured confounders, black per-
sons have 0.71 times the odds of reporting OPR misuse (OR = 0.71, 95% CI = 0.55, 0.93) com-
pared to their white counterparts, i.e., blacks are at an approximately 29% lower risk of OPR
misuse than whites. Compared with the total effect, in all three controlled direct effect models
the black-white disparity widens (coefficient gets further away from 1) suggesting that if no
one were discriminated against, black persons would be at an even lower risk of OPR misuse
compared to whites. Adjusting for all measured confounders, the controlled direct effect in
model 2 suggests that when everyone is set to being not discriminated against (M = 0), black
Table 1. Baseline characteristics of study participants by race, CARDIA study, 1992–2015.
Black
n = 1717
White
n = 1811
P value
Age (years), mean, (SD) 31 (3.8) 32 (3.4) <0.01
Female, n, (%) 1040 (60.6) 998 (54.6) <0.01
Years of education, mean, (SD) 13.84 (2.1) 15.6 (2.5) <0.01
Household income ($), mean, (SD) $32,027.5 ($18,492.4) $43,633.9
($19980.1)
<0.01
Parental years of education, mean, (SD) 12.79 (2.7) 14.92 (3.1) <0.01
Had health insurance, n, (%) 1259 (73.3) 1456 (80.4) <0.01
CARDIA study site, n, (%) <0.01
Birmingham, n, (%) 469 (27.3) 375 (20.7)
Chicago, n, (%) 355 (20.7) 427 (23.5)
Minneapolis, n, (%) 339 (19.7) 571 (31.5)
Oakland, n, (%) 554 (32.3) 438 (24.2)
CES-D score�16, n, (%) 462 (26.9) 297 (16.4) <0.01
Racial discrimination in a medical care setting, n, (%) 350, (20.4) 17 (0.9) <0.01
OPR Misuse 2000–2015, n, (%) 100 (5.8) 145 (8.0) <0.01
N is number of participants, SD is standard deviation. P values are from χ2 tests for categorical variables and t tests for continuous variables. CES-D: Center for
Epidemiological Studies Depression Score, taken in 1990. All other covariates were measured in 1992; OPR: Opioid Pain Reliever, measured after 2000
https://doi.org/10.1371/journal.pone.0226490.t001
Table 2. Relationship of race, discrimination in a medical setting, and OPR misuse using causal mediation methods, CARDIA study (N = 3528).
Total effect (model 1) CDE: Adjusted for
discrimination and
confounders
(model 2)
CDE: Adjusted for
discrimination,
confounders, and
confounders/mediators
(model 3)
Marginal structural model
(model 4)
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Black vs. white 0.71 (0.55, 0.93) 0.63 (0.45, 0.89) 0.55 (0.38, 0.80) 0.65 (0.46, 0.91)
No discrimination vs. discrimination 0.54 (0.34, 0.86) 0.50 (0.31, 0.83) 0.51 (0.31, 0.83)
OR is odds ratio, CI is confidence interval, N is number of participants, CDE is controlled direct effect. Model 1 is adjusted for race; Model 2 is adjusted for race,
medical discrimination and confounders (parental SES, age, sex, and study site); Model 3 is adjusted for race, medical discrimination, confounders (parental SES, age,
sex, and study site), and confounders/mediators (education, income, depressive symptoms, and insurance status); Model 4 is adjusted for race and medical
discrimination, and uses stabilized inverse probability weights to account for the confounders and confounders/mediators (see supplemental SAS code).
https://doi.org/10.1371/journal.pone.0226490.t002
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persons would have 0.63 times the odds of reporting OPR misuse (OR = 0.63, 95% CI = 0.45,
0.89) compared to their white counterparts, i.e. blacks would have a 37% lower risk of OPR
misuse. Adjusting for all measured confounders as well as confounders/mediators, the con-
trolled direct effect in model 3 suggests that when everyone is set to being not discriminated
against (M = 0), black persons would have 0.55 times the odds (45% lower risk) of reporting
OPR misuse (OR = 0.55, 95% CI = 0.38, 0.80) compared to their white counterparts. Finally,
the controlled direct effect in model 4 which uses stabilized weights to account for measured
confounding, suggests that when everyone is set to being not discriminated against (M = 0),
black persons would have 0.65 times the odds (35% lower risk) of reporting OPR misuse
(OR = 0.65, 95% CI = 0.46, 0.91) compared to their white counterparts.
The results of our four sensitivity analyses can be seen in S1 Table, S2 Table, and S3 Table.
In our first sensitivity analysis (S1 Table), we assessed measurement error in the lifetime dis-
crimination measure by excluding 127 participants who inconsistently responded to the dis-
crimination measure across years 1992 and 2000, and our results were largely similar to those
seen in our main analysis (Table 2). In our second sensitivity analysis (S2 Table) including
only “recent” experience of discrimination in a medical setting, our sample size of persons
who experienced discrimination was drastically reduced (n = 116) and thus we were unable to
draw conclusions from these models, however the point estimates were in the same direction
as our main analysis. In our sensitivity analysis adjusting for self-reported pain as a confounder
(S3 Table), the results were also similar to those seen in Table 2.
Discussion
By comparing the total effects and controlled direct effects from our models, we show that dis-
crimination in a medical setting increases a person’s risk of OPR misuse rather than being pro-
tective against OPR misuse. Our findings are counter to our original hypothesis that
discrimination in a medical setting would be protective against iatrogenic (i.e. unintentionally
harmful) effects of healthcare-related opioid misuse and thus a mediator of the black-white
disparity. While our total effect of 0.71 suggests that blacks have lower odds of OPR misuse
compared to whites–which is in line with the established rates of racial disparity in OPR mis-
use[3, 5]–in our final model our controlled direct effect of 0.65 became more protective (i.e.
further away from one), thus widening the disparity and suggesting that discrimination in a
medical setting is a risk factor, rather than a protective factor, for OPR misuse.
We hypothesized that racial discrimination in a medical setting would result in less treat-
ment and thus under prescribing of OPR to blacks, which would then result in lower OPR mis-
use among blacks, and thus explain the observed black-white disparity. As our findings were
counter to our hypothesis, we must consider the possibility that misused OPR medications
originated from potential sources other than the medical setting, such as the diversion of OPR
medications and black market sale of these medications. A recent paper estimated that 42% of
OPRs prescribed in the emergency department may be ultimately misused, either by the
patient or persons close to them[20]. Given these diversion rates, prescribing practices may
have little impact on the actual availability of OPR medications for persons who would misuse
them. Future studies using mediation analysis to examine the black-white disparity in OPR
misuse, and with more detailed survey questions or criminal justice data, should account for
the possible source of OPR medications. This could be a larger problem in the future, as recent
research points to a new shift in the opioid epidemic since 2010, wherein the large disparity in
black versus white OPR misuse from the 1990s to 2010 (largely driven by prescription OPRs)
has narrowed in recent years due to the return to synthetic and illicit OPRs[6].
Racial discrimination in medical care settings and opioid pain reliever misuse
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Another possible explanation for the findings related to the influence of discrimination is
that the black—white disparity in OPR misuse is not a result of discrimination in medical set-
tings, but other factors influencing racial differences in misuse of illicit opioids vs prescription
OPR. While the focus of this paper is not illicit nonprescription opioids such as heroin, there
were more blacks than whites who reported lifetime heroin misuse in the years after 2010 (6
whites vs 28 blacks reporting new lifetime heroin misuse after 2000). It is outside of the scope
of these data to determine whether these differences in heroin misuse may be a result of other
factors related to discrimination in medical care settings. Given the knowledge that there are
known racial biases in OPR prescribing, it is possible that the lesser rate of OPR misuse among
blacks could be offset by a higher rate of heroin misuse among blacks. While the black-white
disparity in opioid misuse persists, other research suggests there are recent increases in illicit
opioid misuse among blacks, which would be consistent with this alternate explanation[6, 21].
A third and related possible explanation for the findings is that there was not discrimina-
tory prescribing practices influencing racial disparities in the opioid epidemic, but rather cau-
tious prescribing to black persons to intentionally protect them from these drugs of potential
abuse out of concern for the well-being of black patients. This explanation is plausible given
the findings of this research, however, this explanation is not supported by the well docu-
mented history of discriminatory and unequal provision of care in OPR prescribing[7, 8] and
healthcare as a whole[22]. Future studies could benefit from using qualitative and mixed meth-
ods approaches to identify alternative explanations for racial disparities in the opioid epidemic.
Information from prescribers and drug counselors, black market contexts, as well as on the
social histories of disparities of drug misuse would enrich our understanding of racial dispari-
ties in OPR misuse.
Our findings suggest that discrimination in a medical setting is a risk factor for OPR mis-
use. The relationship between discrimination in a medical care setting and OPR misuse we
found is likely similar to the relationship observed between discrimination in any other setting
and negative outcomes. In this cohort, experiences of discrimination in any setting have been
associated with several negative health outcomes, including lower birthweight among mothers
who reported such experiences[23], greater waist circumference[24], and increased sedentary
behaviors[25]. There is also a large body of evidence supporting the relationship between per-
ceived discrimination across all settings and increased substance misuse and risky behaviors
among both whites, blacks and other groups[26–33], suggesting that substance misuse could
be a coping mechanism for discrimination, regardless of the race or ethnicity. Further analysis
could investigate similar mechanisms in the relationship between discrimination and OPR
misuse. In a meta-analysis, discrimination in various settings was associated with worse mental
health, physical health, heightened stress responses and importantly, participation in
unhealthy behaviors[33]. Given that recent research has shown increases in black OPR over-
dose and shifting demographics[6, 21, 34], the results of this analysis may also be useful to
inform prevention of OPR misuse among blacks. However, it is important to acknowledge
that other factors may be stronger predictors of OPR misuse and therefore more important for
informing prevention efforts.
Our study has several limitations. In CARDIA, we did not have an objective measure of
OPR misuse such as by hair or urine testing. As a small number of whites reported being dis-
criminated against in a medical setting (n = 17), this may have affected the precision of the esti-
mate among whites only. While the present study collects data on OPR misuse, it does not
collect information on whether participants were actually prescribed the OPR in a medical set-
ting. Furthermore, we are unable to ascertain whether a medical provider who discriminated
against study participants was likely to prescribe OPRs, or any other medications. There are
limitations to the measure of perceived discrimination in epidemiological studies. These
Racial discrimination in medical care settings and opioid pain reliever misuse
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measures capture discrimination as perceived and reported by participants, which could
possibly result in subjective misreporting of discrimination based on factors related to the
participants’ experiences in healthcare. By focusing on individual-level experiences of dis-
crimination, the perceived measure of discrimination may be missing macro-level sources of
discrimination (institutional, policy, etc.). While study participants may be aware of discrimi-
nation happening at these levels, it is not captured in our current measure of discrimination.
Our discrimination measure was treated as a binary yes/no question, and thus does not con-
sider that some experiences of discrimination may be more severe than others. However, since
there are currently no gold standard measures for capturing discrimination in epidemiological
studies we believe using the perceived discrimination measure makes an important contribu-
tion to the literature despite these limitations. A final consideration is that the CARDIA cohort
does not include persons from certain geographic regions of the United States or persons at
high risk for substance misuse, and as such our findings regarding the experiences of discrimi-
nation and their effect on OPR misuse may not be generalizable to other study populations. In
spite of these limitations, the results of this study do provide an indication that this type of
interpersonal discrimination impacts misuse of OPRs, in a way that is similar to the docu-
mented relationships between perceived discrimination, mental health outcomes, and other
substances of abuse [26–33].
Our study has several strengths that contribute to the current literature. The CARDIA
study is one of few cohort studies with questions, repeated over time, on both discrimination
in a medical care setting and OPR misuse. Although there is no objective or gold standard
measure of discrimination, the experiences of discrimination instrument (EOD) used in
this analysis has been previously validated, making this sample well suited for this research
question[14]. We performed several sensitivity analyses and our results were unchanged, sup-
porting the conclusions of our analyses. To account for the test/ retest validity of our discrimi-
nation measures we performed two sensitivity analyses using different definitions. In one
analysis, we excluded participants who flipped their answer to the experience of discrimination
between the 1992 and 2000 exam years, and results were unchanged. In another, we restricted
the analysis to participants who experienced recent discrimination instead of lifetime discrimi-
nation–though we did not have the sample size to detect significance, the point estimates in
our final model were similar to our main analysis. Finally, the CARDIA study is a cohort study
with data from the 1990s to the present, so we were able to establish a temporal sequence
between our predictor (discrimination up to year 2000) and our outcomes (OPR misuse after
2000), which was the time with the largest increase in OPR misuse in the history of the United
States.
To our knowledge, there is currently no literature on whether discrimination in a medical
care setting impacts OPR misuse, and the United States is amid an OPR misuse epidemic. Our
findings were consistent with other studies that have found that whites report OPR misuse at
higher rates than blacks[1, 5, 6, 21, 35]. Our study further suggests that discrimination
increases a person’s risk of OPR misuse for both black and white persons rather than being
protective against OPR misuse for blacks, and thus did not explain the black–white disparity.
Our objective in this manuscript was not to identify risk factors for OPR misuse specifically,
but rather to posit a possible explanation for racial disparities in OPR misuse. However, given
that discriminatory treatment in a medical care setting (or any other setting) is never accept-
able, in this study we have identified discrimination in a medical setting as a potential modifi-
able target for alleviating OPR misuse, acknowledging that other research is necessary to fully
inform the prevention of OPR misuse. Further research is needed to investigate the complex
mechanisms behind the black–white disparity in OPR misuse, including the source of OPR
medications.
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